KMT2A

Across TCGA pan-cancer cohorts, KMT2A Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated KMT2A data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher KMT2A Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated KMT2A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, SCLC, and BRCA are the cancer types where KMT2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.900	0.298	.005	26	view →
SCLC	OS	Median	II,III,IV	0.205	0.659	.006	18	view →
BRCA	OS	Median	IV	0.106	0.791	<.001	12	view →
ACC	DFS	Median	All	0.068	0.667	.005	12	view →
PAAD	DFS	Median	All	0.126	0.508	.006	6	view →
LGG	OS	Median	All	0.192	0.799	<.001	6	view →
HNSC	OS	Median	III,IV	0.169	0.673	.035	6	view →
COAD	OS	Median	IV	0.045	0.659	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUAD	OS	Median	II,III,IV	0.317	0.565	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

KMT2A–UCEC (DFS)

Open the UCEC breakdown →